
| Clinical Trial Phase I | 2 | Clinical Trial Phase II | 20 | Clinical Trial Phase III | 60 |
| Post-Marketing Surveillance | 15 | Others (clinical pharmacological studies, etc.) | 7 | ||
| Total | 104 | ||||

| CNS medicines *1 | 19 | Oncology medicines/immunosuppressants *2 | 5 | External application *3 | 3 |
| Sensory organs *4 | 3 | Infections *5 | 6 | Cardiovascular *6 | 10 |
| Gastrointestinal *7 | 12 | Endocrinology/metabolic *8 | 20 | Urological *9 | 4 |
| Renal *10 | 8 | Cerebrovascular diseases | 6 | Others (including medical devices) *11 | 8 |
| Total | 104 | ||||
*1 Epilepsy, rheumatoid arthritis, anorexia, cerebrovascular dementia, panic disorder, chronic insomnia, etc.
*2 Malignant neoplasm (e.g. non-small cell lung cancer), rheumatoid arthritis, uterine cervical cancer vaccine
*3 Dermatology/allergies, inflammatory eruption (acne), nail tinea
*4 Ocular hypertension, glaucoma, etc.
*5 Infection, pediatrics/infection, internal medicine/infectious diseases (RTI), sinusitis
*6 Hypertension, cardiac arrest, hyperlipemia, etc.
*7 Gastric ulcer, reflux esophagitis, gastritis, constipation, stomal ulcer, gastroduodenitus
*8 Diabetes mellitus, hepatitis C, osteoporosis
*9 Glomerulonephritis, diabetes insipidus
*10 Chronic kidney disease
*11 Peritoneal dialysate, pediatric vaccine, food for specified health use, implant, etc.

| CNS | 13 | Oncology medicines/immunosuppressants | 6 | External application | 3 |
| Sensory organs | 3 | Infections | 12 | Cardiovascular | 17 |
| Gastrointestinal | 11 | Endocrinology/metabolic | 17 | Urological | 5 |
| Respiratory | 6 | Hormones | 11 | Others (including infusions and medical devices) | 19 |
| Total | 123 | ||||

| Phase I | Enrollment | 0 | Data management | 11 | Statistical analysis | 11 | CSR writing | 3 | 25 | |
| Phase II | Enrollment | 1 | Data management | 41 | Statistical analysis | 14 | CSR writing | 5 | 34 | |
| Phase III | Enrollment | 4 | Data management | 38 | Statistical analysis | 55 | CSR writing | 14 | 111 | |
| Phase IV | Enrollment | 1 | Data management | 4 | Statistical analysis | 4 | CSR writing | 1 | 10 | |
| Others Epidemiological studies |
Enrollment | 0 | Data management | 3 | Statistical analysis | 3 | CSR writing | 0 | 6 | |
| Total | 213 | |||||||||

| Cardiovascular | 43 | Other metabolic | 14 | CNS | 16 |
| Diabetes | 19 | Oncology | 23 | Immunosuppressants | 9 |
| Antibiotics | 15 | Urological | 7 | Gastrointestinal | 9 |
| Hormones | 12 | Respiratory | 5 | Allergies | 5 |
| Peripheral nerve | 4 | Others | 66 | ||
| Total | 247 | ||||

| >10,000 patients | 25 | 6,000 – < 10,000 patients | 16 | 3,000 – < 6,000 patients | 58 |
| 1,000 – < 3,000 patients | 33 | < 1,000 patients | 72 | ||
| Total | 204 | ||||
| ※Excluding 100% surveys | |||||